

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	9875894-00006	Date of first issue: 19.10.2021

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Infliximab Formulation - (OGN)

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Pharmaceutical

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person  
responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## Infliximab Formulation - (OGN)

Version            Revision Date:            SDS Number:            Date of last issue: 04.04.2023  
2.1                30.09.2023                9875894-00006            Date of first issue: 19.10.2021

---

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Infliximab	170277-31-3		>= 10 - < 20

For explanation of abbreviations see section 16.

---

**SECTION 4: First aid measures****4.1 Description of first aid measures**

- General advice                                : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders                    : No special precautions are necessary for first aid responders.
- If inhaled                                        : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact                        : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact                         : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed                                    : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

**4.2 Most important symptoms and effects, both acute and delayed**

- Risks     : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

**4.3 Indication of any immediate medical attention and special treatment needed**

- Treatment                                      : Treat symptomatically and supportively.

## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	9875894-00006	Date of first issue: 19.10.2021

---

**SECTION 5: Firefighting measures****5.1 Extinguishing media**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

**5.2 Special hazards arising from the substance or mixture**

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

**5.3 Advice for firefighters**

Special protective equipment for firefighters : Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

**SECTION 6: Accidental release measures****6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and material for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfac-

## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	9875894-00006	Date of first issue: 19.10.2021

---

es, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  |
| Local/Total ventilation | : | Use only with adequate ventilation.   |
| Advice on safe handling | : | Do not breathe dust.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |   |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents                           |

### 7.3 Specific end use(s)

- |                 |   |  |
|-----------------|---|--|
| Specific use(s) | : | No data available<br><br>No data available |
|-----------------|---|--|
- 

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version 2.1      Revision Date: 30.09.2023      SDS Number: 9875894-00006      Date of last issue: 04.04.2023  
Date of first issue: 19.10.2021

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sucrose	57-50-1	OEL-RL	10 mg/m <sup>3</sup>	ZA OEL
Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents				
Infliximab	170277-31-3	TWA	150 µg/m <sup>3</sup>	Internal

### 8.2 Exposure controls

#### Engineering measures

Ensure adequate ventilation, especially in confined areas.  
Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

#### Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:  
Safety goggles

Hand protection

Material : Chemical-resistant gloves

Remarks : For prolonged or repeated contact use protective gloves.  
Wash hands before breaks and at the end of workday.

Skin and body protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Appearance : Amorphous powder

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : 7,2

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	9875894-00006	Date of first issue: 19.10.2021

---

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	1 g/cm <sup>3</sup>
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

**9.2 Other information**

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

**10.4 Conditions to avoid**

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
---------------------	---	---

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version 2.1      Revision Date: 30.09.2023      SDS Number: 9875894-00006      Date of last issue: 04.04.2023  
Date of first issue: 19.10.2021

---

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Infliximab:

Remarks : No data available

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Infliximab:

Remarks : No data available

#### Respiratory or skin sensitisation

##### Skin sensitisation

Not classified based on available information.

##### Respiratory sensitisation

Not classified based on available information.

##### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Infliximab:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: Chromosomal aberration  
Test system: human lymphoblastoid cells

## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	9875894-00006	Date of first issue: 19.10.2021

---

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Method: OECD Test Guideline 474  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Infliximab:**

Effects on fertility : Test Type: Fertility  
Species: Mouse  
Application Route: Intravenous injection  
Fertility: NOAEL: 40 mg/kg body weight  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse, female  
Application Route: Intravenous injection  
Duration of Single Treatment: 6 - 12 d  
General Toxicity Maternal: NOAEL: 40 mg/kg body weight  
Teratogenicity: NOAEL F1: 40 mg/kg body weight  
Developmental Toxicity: NOAEL F1: 40  
Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight  
Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Infliximab:**

Species : Mouse  
NOAEL : 40 mg/kg  
Application Route : Intravenous  
Exposure time : 6 Months  
Number of exposures : daily

**Aspiration toxicity**

Not classified based on available information.



## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	9875894-00006	Date of first issue: 19.10.2021

---

**Experience with human exposure****Components:****Infliximab:**

Inhalation : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, Fatigue, Headache, Back pain

---

**SECTION 12: Ecological information****12.1 Toxicity****Components:****Infliximab:****Ecotoxicology Assessment**

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

**12.2 Persistence and degradability**

No data available

**12.3 Bioaccumulative potential**

No data available

**12.4 Mobility in soil**

No data available

**12.5 Results of PBT and vPvB assessment****Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**12.6 Other adverse effects****Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.

---

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version 2.1      Revision Date: 30.09.2023      SDS Number: 9875894-00006      Date of last issue: 04.04.2023  
Date of first issue: 19.10.2021

---

Contaminated packaging : Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.  
Do not dispose of waste into sewer.  
Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

### SECTION 14: Transport information

#### 14.1 UN number

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

#### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

#### 14.4 Packing group

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA (Cargo) : Not regulated as a dangerous good  
IATA (Passenger) : Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

#### 14.6 Special precautions for user

Not applicable

#### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	9875894-00006	Date of first issue: 19.10.2021

Remarks : Not applicable for product as supplied.

### SECTION 15: Regulatory information

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

#### Full text of other abbreviations

ZA OEL : South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits

ZA OEL / OEL-RL : Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative)

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	9875894-00006	Date of first issue: 19.10.2021

---

tative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN